GSK swears off commercial CME providers

Share this article:

GlaxoSmithKline is cutting off commercial CME providers, following Pfizer's lead.

GSK said starting next year, it will fund only “independent” CME programs designed to close gaps in patient care, and that effective immediately, it will no longer fund CME executed by commercial providers, including medical education and communication companies.

“GSK will not support as many medical education programs, but we will continue funding those with the greatest potential to improve patient health,” said GSK president, North America Deirdre Connelly in a statement.

The company will invite grant applications from a pool of around potential grant applicants limited to academic medical centers and affiliated teaching and patient care institutions as well as national medical societies and professional groups.

Pfizer announced a similar policy in 2008.

Publishing and education companies received $463 million in commercial support in 2008 – about 44% of the $1 billion doled out that year, according to data from the Accreditation Council for Continuing Medical Education. 

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.